Back

Sinus rate and QRS duration on lead V1 predict major events in Brugada syndrome

17 April 2023 (08:40 - 09:40)
Organised by:
Congress Presentation Part of: ePoster session 20 Epidemiology, Prognosis, Outcome EHRA Premium Access EHRA 2023

About the speaker

Photo
Mr Pierre Leo Laporte

Hospital Bichat-Claude Bernard, Paris (France)

7 More presentations in this session

Presentation thumbnail
Whether and what abnormalities we find in ECG records and 24-hour Holter ECG in patients after COVID-19 without hospitalization with cardiac damage.
Doctor M. Chudzik (Warsaw, PL)
Abstract Slides
Presentation thumbnail
Clinical significance of the DUS4ABL strategy for systematically guiding left atrial and ventricular electrophysiological procedures
Doctor N. Augustin (Duesseldorf, DE)
Abstract Slides
Presentation thumbnail
A single atrial stimulation resetting his bundle during tachycardia: a new diagnostic methods of atrial tachycardia distinguishing from other tachycardias
Doctor O. Inaba (Saitama, JP)
Abstract Slides
Presentation thumbnail
Catheter ablation of atrial fibrillation and atrial tachycardia in patients with pulmonary hypertension: a randomised study
Associate Professor S. Havranek (Prague, CZ)
Abstract Slides
Presentation thumbnail
Impact of hemodynamic support in high-risk VT ablation procedures
Doctor A. Luik (Karlsruhe, DE)
Abstract Slides

Access the full session

Session thumbnail
ePoster session 20

The Event

Event poster

EHRA 2023

17 April 2023 08:40 CET
You may be interested in
thumbnail
Congress Presentation
Electrophysiologic study for risk stratification in Brugada Syndrome: does it still matters?
27 August 2021
thumbnail
Congress Presentation
Remote monitoring can predict lethal arrhythmic events through time-domain analysis of heart rate variability in patients with implantable cardioverter defibrillator
28 August 2020
thumbnail
Congress Presentation
Frontal QRS/T angle can predict mortality in COVID-19 patients
28 August 2021
thumbnail
Congress Presentation
Structured optimization of QRS duration reduction post-Cardiac Resynchronization Therapy is feasible and shorter QRS duration is associated with better clinical outcome
4 April 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources